T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.

ABSTRACT: Acute myeloid leukemia (AML) is a heterogeneous disease linked to a broad spectrum of molecular alterations, and as such, long-term disease control requires multiple therapeutic approaches. Driven largely by an improved understanding and targeting of these molecular aberrations, AML treatment has rapidly evolved over the last 3-5 years. The stellar successes of immunotherapies that harness the power of T cells to treat solid tumors and an improved understanding of the immune systems of patients with hematologic malignancies have led to major efforts to develop immunotherapies for the treatment of patients with AML. Several immunotherapies that harness T cells against AML are in various stages of preclinical and clinical development. These include bispecific and dual antigen receptor-target

SUBMITTER: Daver N 

PROVIDER: S-EPMC8257483 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature